No Data
Botu Biological (688767.SH): Cumulative repurchase of 2.02% of shares, the buyback plan has been completed.
On July 24th, Gelonhui announced that the company's share buyback plan has been completed as of the date of this announcement. The company has repurchased a total of 2,150,000 shares through centralized bidding trading, accounting for 2.02% of the company's total share capital. The highest purchase price was 33.48 yuan/share, the lowest was 22.23 yuan/share, and the average purchase price was 26.95 yuan/share. The total amount paid was RMB 57,949,678.66 (excluding stamp duty, transaction fees, and other expenses).
Biotools (688767.SH): spent a total of 56.93 million yuan to repurchase 1.978% of the shares.
On July 1st, Gelunhui reported that Botro Biotechnology (688767.SH) had repurchased a total of 2,109,838 shares of the company through the Shanghai Stock Exchange trading system by means of centralized bidding trading as of June 30, 2024, accounting for 1.9780% of the company's total share capital of 106,666,667 shares. The highest price of the repurchase transaction was 33.48 yuan/share, the lowest price was 22.23 yuan/share, and the total amount of funds paid was RMB 56,930,164.60 (excluding stamp duty, transaction commission and other transaction fees).
Botuo Biotech (688767.SH) will distribute 8 yuan for every 10 shares in 2023. The stock registration date is June 7
Botuo Biotech (688767.SH) announced that the company will implement the 2023 annual equity distribution to all shares...
Botuo Biotech (688767.SH): Has repurchased a total of 2.109,800 shares of the company's shares
Gelonghui, June 2, 丨 Botuo Biotech (688767.SH) announced that as of May 31, 2024, the company had repurchased 2.109,800 shares of the company's shares through centralized bidding transactions, accounting for 1.9780% of the company's total share capital. The highest price of the repurchase transaction was 33.48 yuan/share, the lowest price was 22.23 yuan/share, and the total amount of capital paid was RMB 569.32 million (excluding transaction fees such as stamp duty and transaction fees).
Botuo Biotech (688767.SH): Currently, POCT industry competition is fierce, and POCT products are under pressure to reduce prices
Gelonghui, May 13 | Botuo Biotech (688767.SH) recently said during a survey reception from institutional investors that currently the POCT industry is fiercely competitive, and POCT products are under certain price reduction pressure.
Botuo Biotech (688767.SH): Will continue to focus on POCT testing tracks
Gelonghui, May 13 | Botuo Biotech (688767.SH) recently said during a survey receiving institutional investors that the company will continue to focus on the POCT testing circuit, give full play to the technology, product, quality and sales advantages that the company has accumulated over the years, and launch new products with higher cost performance, higher sensitivity, and closer to customer usage needs in colloidal gold technology. In terms of new technology platforms, efforts are being made to expand the variety of immunofluorescence products, increase the number of registration certificates for immunofluorescence products, further improve product quality through microfluidic control technology, and create new technology products with differentiated advantages. At the same time, the company is working hard to find the right shape on the outside
No Data
